(Q40288993)

English

Vif-deficient HIV reverse transcription complexes (RTCs) are subject to structural changes and mutation of RTC-associated reverse transcription products

scientific article published on 2 May 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

Vif-deficient HIV reverse transcription complexes (RTCs) are subject to structural changes and mutation of RTC-associated reverse transcription products (English)

1 reference

Europe PubMed Central

19 September 2017

author name string

J M Carr

1

1 reference

Europe PubMed Central

19 September 2017

A J Davis

2

1 reference

Europe PubMed Central

19 September 2017

C Coolen

3

1 reference

Europe PubMed Central

19 September 2017

K Cheney

4

1 reference

Europe PubMed Central

19 September 2017

C J Burrell

5

1 reference

Europe PubMed Central

19 September 2017

P Li

6

1 reference

Europe PubMed Central

19 September 2017

language of work or name

0 references

publication date

2 May 2006

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

351

1 reference

Europe PubMed Central

19 September 2017

1

1 reference

Europe PubMed Central

19 September 2017

80-91

1 reference

Europe PubMed Central

19 September 2017

Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Cytidine deamination of retroviral DNA by diverse APOBEC proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

APOBEC-mediated editing of viral RNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

The interaction between HIV-1 Gag and APOBEC3G.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

DNA deamination mediates innate immunity to retroviral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Characterization of HIV replication complexes early after cell-to-cell infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

APOBEC3G targets specific virus species.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Hypermutation of HIV-1 DNA in the Absence of the Vif Protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Synthesis of human immunodeficiency virus DNA in a cell-to-cell transmission model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Functional domains of APOBEC3G required for antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

The barrier-to-autointegration factor is a component of functional human immunodeficiency virus type 1 preintegration complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Visualization of the intracellular behavior of HIV in living cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

The replicative impairment of Vif- mutants of human immunodeficiency virus type 1 correlates with an overall defect in viral DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Complementary function of the two catalytic domains of APOBEC3G.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Kinetics of human immunodeficiency virus type 1 (HIV) DNA integration in acutely infected cells as determined using a novel assay for detection of integrated HIV DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of Vif in human immunodeficiency virus type 1 reverse transcription

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.027

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2006.03.027

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40288993&oldid=1893495988"